Bloodstream infections in patients with chronic lymphocytic leukemia: a longitudinal single-center study

被引:10
|
作者
Kjellander, Christian [1 ,2 ,3 ]
Bjorkholm, Magnus [1 ,2 ]
Kallman, Owe [4 ,5 ]
Giske, Christian G. [4 ,5 ]
Weibull, Caroline E. [6 ]
Love, Thorvardur J. [7 ,8 ,10 ,11 ]
Landgren, Ola [9 ]
Kristinsson, Sigurdur Y. [1 ,2 ,10 ,11 ]
机构
[1] Karolinska Univ Hosp Solna, Dept Med, Div Hematol, Stockholm, Sweden
[2] Karolinska Inst, Stockholm, Sweden
[3] Karolinska Univ Sjukhuset Solna, Hematol Ctr, S-17176 Stockholm, Sweden
[4] Karolinska Univ Hosp, Clin Microbiol, Stockholm, Sweden
[5] Karolinska Inst, Dept Lab Med, Stockholm, Sweden
[6] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden
[7] Landspitali Univ Hosp, Ctr Rheumatol Res, Reykjavik, Iceland
[8] Univ Iceland, Reykjavik, Iceland
[9] Mem Sloan Kettering Canc Ctr, Dept Med, Myeloma Serv, 1275 York Ave, New York, NY 10021 USA
[10] Univ Iceland, Fac Med, Reykjavik, Iceland
[11] Landspitali Univ Hosp, Reykjavik, Iceland
关键词
Chronic lymphocytic leukemia; Infections; Prognosis; Bloodstream infections; Splenectomy; TRIMETHOPRIM-SULFAMETHOXAZOLE; HEMATOLOGICAL MALIGNANCIES; INITIAL THERAPY; FLUDARABINE; BACTEREMIA; RITUXIMAB; CANCER; CYCLOPHOSPHAMIDE; ALEMTUZUMAB; RESISTANCE;
D O I
10.1007/s00277-016-2643-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Infectious complications in chronic lymphocytic leukemia (CLL) represent a major cause of morbidity and mortality. The aim of the study was to investigate temporal trends in bloodstream infections (BSIs) among patients with CLL. Individuals with blood cultures were linked to Swedish Cancer Registry and divided into three time periods (1988-1993, 1994-1999, and 2000-2006) according to year of CLL diagnosis. CLL patients (n = 275) with 1092 blood culture episodes were identified and linked to the nationwide Cause of Death Registry and Swedish Patient Registry (to retrieve information on splenectomies). The most common causes of BSI among CLL patients were Escherichia coli (11/43, 15/78, and 9/33), Streptococcus pneumoniae (7/43, 13/78, and 6/33), Pseudomonas aeruginosa (2/43, 8/78, and 3/33), Staphylococcus aureus (1/43, 6/78, and 6/33), and Viridans streptococci (5/43, 6/78, and 2/33). Coagulase-negative staphylococci was the most frequent microorganism found in blood cultures (22/70, 23/106, and 5/41, respectively) but is a frequent contaminant. Based on the largest study to date on BSI in CLL patients, we found a stable proportion of Gram-positive to Gram-negative bacteria and no temporal change of distribution was observed for BSIs 1988-2006.
引用
收藏
页码:871 / 879
页数:9
相关论文
共 50 条
  • [11] Epidemiology of bloodstream infections in patients with chronic lymphocytic leukemia: a longitudinal nation-wide cohort study (vol 53, pg 831, 2020)
    Andersen, Michael Asger
    Moser, Claus Ernst
    Lundgren, Jens
    Niemann, Carsten Utoft
    LEUKEMIA, 2020, 34 (10) : 2817 - 2818
  • [12] Ibrutinib Plus Fludarabine, Cyclophosphamide, and Rituximab As the Treatment for Chronic Lymphocytic Leukemia/ Small Lymphocytic Leukemia: A Single-Center Real World Study
    Zhu, Huayuan
    Shen, Hui
    Yang, Yilian
    Ding, Chong-Yang
    Sha, Yeqin
    Mi, Hongling
    Qiu, Jingyan
    Chen, Ruize
    Wu, Yujie
    Qiao, Chun
    Wang, Li
    Fan, Lei
    Xu, Wei
    Li, Jianyong
    BLOOD, 2020, 136
  • [13] COVID-19 severity in patients with chronic lymphocytic leukemia treated with venetoclax: a single-center observational cohort study
    Thau, Sophie
    Poulsen, Christian Bjorn
    Brieghel, Christian
    Larsen, Morten Kranker
    Wiese, Lothar
    Nielsen, Xiaohui Chen
    Pedersen, Lars Moller
    ANNALS OF HEMATOLOGY, 2024, 103 (08) : 3053 - 3060
  • [14] IBRUTINIB IN CHRONIC LYMPHOCYTIC LEUKEMIA: A SINGLE-CENTER LONG-TERM ANALYSIS
    Stefoni, V.
    Broccoli, A.
    Argnani, L.
    Casadei, B.
    Pellegrini, C.
    Nanni, L.
    Morigi, A.
    Carella, M.
    Lolli, G.
    Coppola, P. E.
    Bagnato, G.
    Gentilini, M.
    Zinzani, P. L.
    HAEMATOLOGICA, 2021, 106 (10) : 159 - 159
  • [15] Infections in patients with chronic lymphocytic leukemia
    Guarana, Mariana
    Nucci, Marcio
    HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2023, 45 (03) : 387 - 393
  • [16] Single-center experience of Campath® (alemtuzumab) treatment of refractory chronic lymphocytic leukemia (CLL) patients.
    Saba, HI
    Morelli, GA
    Tannenbaum, B
    Loughran, TP
    BLOOD, 2002, 100 (11) : 365B - 365B
  • [17] Bloodstream infections due to carbapenem-resistant enterobacteriaceae in hematological patients: A retrospective single-center study
    Zhang, L.
    Lin, Q.
    Jiang, E.
    Han, M.
    Wang, J.
    Feng, S.
    BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 284 - 285
  • [18] First Line Treatment of Chronic Lymphocytic Leukemia (CLL) Patients With Obinutuzumab Based Therapy: Single-Center Experience
    Trajkova, Sanja
    Pivkova-Veljanovska, Aleksandra
    Krstevska-Balkanov, Svetlana
    Popova-Labacevska, Marija
    Ridova, Nevenka
    Stojanovska-Jakimovska, Simona
    Cvetanovski, Milche
    Chadievski, Lazar
    Kocoski, Bozidar
    Panovska-Stavridis, Irina
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S326 - S326
  • [19] Outcome of patients with chronic lymphocytic leukemia and acute kidney injury: Single-center experience (2000-2012).
    Anand, Ankit
    Al-Sharif, Hussam
    Linga, Karthika Raya
    Al-Ameri, Ali
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [20] Epidemiology and risk factors for mortality in bloodstream infections: A single-center retrospective study in Japan
    Hattori, Haruka
    Maeda, Masayuki
    Nagatomo, Yasuhiro
    Takuma, Takahiro
    Niki, Yoshihito
    Naito, Yuika
    Sasaki, Tadanori
    Ishino, Keiko
    AMERICAN JOURNAL OF INFECTION CONTROL, 2018, 46 (12) : E75 - E79